AbbVie and Umoja Biopharma announced the signing of two exclusive option and license agreements to develop multiple in-situ generated CAR-T cell therapy candidates in oncology using Umoja’s proprietary VivoVec platform.
Under the initial deal, AbbVie has an exclusive option to license Umoja’s CD19-directed in-situ generated CAR-T cell therapy candidates. This includes Umoja’s UB-VV111, the lead clinical program for hematologic malignancies currently at the IND-enabling phase.
Free access provides up to 10 articles
Subscription options start at $5 per month
which is less than a Starbucks coffee!